McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 8, 2018, Pages 1656-1664

  Legault, K ^a   Schunemann, H ^a   Hillis, C ^a   Yeung, C ^a   Akl, E A ^a,b   Carrier, M ^c   Cervera, R ^d   Crowther, M ^a   Dentali, F ^e   Erkan, D ^f   Espinosa, G ^d   Khamashta, M ^g   Meerpohl, J J ^h   Moffat, K ^a,i   O'Brien, S ^j   Pengo, V ^k   Rand, J H ^f   Rodriguez Pinto, I ^l   Thom, L ^m   Iorio, A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF INSUBRIA   (Italy)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^j NATIONWIDE CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF PADOVA   (Italy)

^l HOSPITAL CLÍNIC   (Spain)

^m Oxford   (United Kingdom)

more..

Author keywords

antibodies, antiphospholipid; antiphospholipid syndrome; practice guideline; rare diseases; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY; RITUXIMAB;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASEPTIC MENINGITIS; BIOPSY; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CLINICAL DECISION MAKING; CONSENSUS DEVELOPMENT; DISEASE CLASSIFICATION; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FLUID RETENTION; HEMOLYSIS; HUMAN; HYPERGLYCEMIA; IMMUNE DEFICIENCY; MOOD DISORDER; MORTALITY; PATIENT PREFERENCE; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS;

EID: 85050931512     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14192     Document Type: Article

References (30)

1. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508–12
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306
3. European Parliament and Council of the European Union. REGULATION (EC) No 141/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 1999 on orphan medicinal products. ec.europa.eu
4. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, Font J, Asherson RA; CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies). Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54: 2568–76
5. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, Shoenfeld Y, Ingelmo M, Espinos G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 2009; 32: 240–5
6. Asherson RA, Espinosa G, Cervera R, Font J, Reverter JC. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol 2002; 8: 157–65
7. Pai M, Iorio A, Meerpohl J, Taruscio D, Laricchiuta P, Mincarone P, Morciano C, Leo C, Sabina S, Akl EA, Treweek S, Djulbegovic B, Schunemann HJ. Developing methodology for the creation of clinical practice guidelines for rare diseases: A report from RARE-Bestpractices. Rare Dis 2015; 3: e1058463
8. Schünemann HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R, Ventresca M, Brignardello-Petersen R, Laisaar K-T, Kowalski S, Baldeh T, Zhang Y, Raid U, Neumann I, Norris SL, Thornton J, Harbour R, Treweek S, Guyatt G, Alonso-Coello P, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ 2014; 186: E123–42
9. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–6
10. Cervera R, Font J, Gómez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, Ramos-Casals M, Ingelmo M, Piette JC, Shoenfeld Y, Asherson RA; Catastrophic Antiphospholipid Syndrome Registry Project Group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1205–9
11. Devreese KMJ, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 792–5
12. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–40
13. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, Pierangeli SS. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64: 1–10
14. Berman H, Rodríguez-Pintó I, Cervera R, Gregory S, de Meis E, Rodrigues CEM, Aikawa NE, de Carvalho JF, Springer J, Niedzwiecki M, Espinosa G; Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev 2014; 13: 157–62
15. Hanouna G, Morel N, Le THD, Josselin L, Vauthier-Brouzes D, Saadoun D, Kettaneh A, Levesque K, Le Guern V, Goffinet F, Carbonne B, Amoura Z, Piette J-C, Nizard J, Costedoat-Chalumeau N. Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology (Oxford) 2013; 52: 1635–41
16. Shiber S, Yair M. Catastrophic antiphospholipid syndrome: a case series. Isr Med Assoc J 2013; 15: 481–4
17. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, Montori VM, Brito JP, Norris S, Elbarbary M, Post P, Nasser M, Shukla V, Jaeschke R, Brozek J, Djulbegovic B, Guyatt G. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013; 66: 726–35
18. Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e24S–43S
19. Berman H, Rodríguez-Pintó I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y, Espinosa G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12: 1085–90
20. Stojanovich L. The catastrophic antiphospholipid syndrome in Serbia: diagnostic and management problems. Clin Rev Allergy Immunol 2009; 36: 98–103
21. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1727 procedures. J Clin Apher 2007; 22: 270–6
22. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190–207
23. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27: 171–8
24. García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS ONE 2016; 11: e0160046
25. Eikelboom JW, Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost 2007; 5(Suppl 1): 255–63
26. Kasper D, Fauci AS, Hauser S, Longo DL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 19e, 19th edn. New York: McGraw-Hill, 2014
27. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37: 558–67
28. Chey WD, Wong BCY; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808–25
29. Knaapen L, Schaefer C, Boivin A, Chalmers S, Davino-Ramaya CM, Gracia J, Rosenfeld R, Røsvik AH, Sakala C, Tyrrell H, Wang M, van der Weijden T. G-I-N PUBLIC toolkit: patient and public involvement in guidelines. 2015. http://www.g-i-n.net/working-groups/gin-public/toolkit. Accessed 3 May 2017
30. Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis 2014; 9: 170